


Malaysian Genomics To Collaborate on Cannabinoid R&D

Group joins MAHSA University and Kensana Health to develop phytopharmaceutical and biotechnology products for commercialisation

PETALING JAYA, 24 February 2023 – **Malaysian Genomics Resource Centre Berhad** (“Malaysian Genomics” or “the Group”), a leading genomics and biopharmaceutical specialist, today announced that the Group has entered into a strategic collaboration with **Kensana Health Canada** and **MAHSA University** for the research and development (“R&D”) of phytopharmaceutical and biotechnology products that can lead to commercialisation.

Kensana Health Canada is a biotechnology specialist focused on the R&D of cannabinoid treatments and management of wounds partnered with a German multinational phytopharmaceutical company. MAHSA University is a private Malaysian university focused on allied health sciences with a 48-acre campus in Bandar Saujana Putra, Selangor and a diverse population of students from 75 countries.

The strategic collaboration involves all three parties conducting joint R&D on species improvement, identification, formulation and pre-clinical testing of novel phytochemicals with potential therapeutic and commercial value, among other areas.



Dato' Alvin Joseph Nesakumar, Executive Director of Malaysian Genomics said, “The Group welcomes this strategic collaboration with MAHSA and Kensana to expand R&D activities utilising plant-based formulations to produce results that can be commercialised in countries where the law allows the use of cannabinoid medications. [In Malaysia, there are also moves to register cannabidiol products this year.](#)”

We have the market knowledge and expertise in the distribution of healthcare-related products while our track record of collaborations and partnerships will help support the Group’s focus on the biopharmaceuticals business for growth and sustainability. We also have necessary lab equipment to support the R&D efforts.”

###

ABOUT MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD

Malaysian Genomics Resource Centre Berhad (“MGRC” or “the Group”) is a leading genomics and biopharmaceutical company based in Southeast Asia. The Group was established in 2004 and listed on the Bursa Malaysia stock exchange in 2010. From pioneering work in genome sequencing, bioinformatics analysis, and genetic screening services, MGRC has expanded into the biopharmaceutical sector with the manufacturing of cell therapies including immunotherapy for various types of cancer.

Utilising its high-throughput sequencing lab, advanced microarray facility, and new state-of-the-art cell processing lab, the Group is committed to improving access to the latest in precision and personalised healthcare solutions to improve the lives of patients.

For more information, visit www.mgrc.com.my.

Issued By: Swan Consultancy Sdn. Bhd. on behalf of Malaysian Genomics Resource Centre Berhad
Date: 24 February 2023

For more information, please contact:

Jazzmin Wan

Tel: +60 17-289 4110

Email: j.wan@swanconsultancy.biz

Amida Baharim

Tel: +60 12-206 1209

Email: a.baharim@swanconsultancy.biz
